No Transplant, No Problem: Redefining First-Line Myeloma Care With Anti-CD38 Therapies
A panelist reviews current evidence-based strategies for managing transplant-ineligible multiple myeloma, focusing on frontline anti-CD38–based regimens supported by trials like IMROZ and CEPHEUS, compares available therapies in terms of efficacy, safety, and administration route—including the quality-of-life benefits of subcutaneous options—and evaluates real-world data to guide treatment selection, value-based care, and equitable access for non-transplant candidates.
EP. 1: Shifting Standards of Care: Insights from CEPHEUS on Anti-CD38 Therapy
July 31st 2025An expert discusses how frontline management of transplant-ineligible multiple myeloma has progressed from melphalan-based regimens to modern anti-CD38–based combinations, now including emerging quadruplet strategies. He highlights data showing improved responses and progression-free survival (PFS) even in frail populations, while emphasizing the need to balance efficacy with treatment burden, especially for older adults with comorbidities.
Watch
An expert discusses how adding an anti-CD38 antibody to a triplet backbone improved minimal residual disease (MRD) negativity and progression-free survival (PFS) in frail, transplant-ineligible patients with multiple myeloma. He also raises concerns about the real-world feasibility of intensive regimens and emphasizes the need for personalized dosing and further research on using MRD to guide treatment duration and intensity.
Watch
An expert discusses how choosing between triplet and quadruplet regimens for transplant-ineligible multiple myeloma depends on patient fitness, disease risk, and treatment tolerability. He highlights that anti-CD38 antibodies generally add minimal toxicity, triplets may offer strong outcomes for frail patients, and practical factors such as infection risk, dosing frequency, and subcutaneous vs intravenous (IV) administration also influence regimen selection.
Watch
EP. 4: The Patient Voice: Practical Factors Influencing Anti-CD38 Therapy Value
August 21st 2025An expert discusses how home administration of oncology drugs in the US faces significant logistical and reimbursement challenges—despite the safety of subcutaneous and on-body delivery systems. He highlights that regulatory barriers, practice economics, and evolving payer policies limit adoption, even as patient-reported outcomes increasingly support the value of well-tolerated, effective regimens such as those studied in MAIA.
Watch
